Abingdon HealthLSE:ABDX Pretax Margin % is -54.24% as of Dec. 2025. The stock has 7 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Abingdon Health ranks worse than 69.46% on this metric.
The historical rank and industry rank for Abingdon Health's Pretax Margin % or its related term are showing as below:
LSE:ABDX'
s Pretax Margin % Range Over the Past 10 Years
Min: -761.66 Med: -62.1 Max: -22.8
Current: -33.02
LSE:ABDX's Pretax Margin % is ranked worse than 69.46% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.56
vs LSE:ABDX: -33.02
Abingdon Health (LSE:ABDX) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Abingdon Health Pretax Margin % Related Terms
Abingdon Health Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Abingdon Health's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:ABDX vs TMO, DHR, IDXX: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, Abingdon Health's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abingdon Health Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Abingdon Health's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Abingdon Health's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abingdon Health (LSE:ABDX) has a Pretax Margin % of -54.24% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Abingdon Health and its competitors. According to the industry distribution chart, Abingdon Health ranks #141 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 69.5%.
Is Abingdon Health's Pretax Margin % too high?
Abingdon Health's current Pretax Margin % is -54.24%. Based on the distribution chart, Abingdon Health ranks #141 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does Abingdon Health's Pretax Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Abingdon Health ranks #141 out of 203 companies for Pretax Margin %. This places Abingdon Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Abingdon Health and its competitors. Abingdon Health's current Pretax Margin % is -54.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abingdon Health stock overvalued right now?
Based on GuruFocus' analysis, Abingdon Health (LSE:ABDX) is currently considered Possible Value Trap. The stock's GF Value™ is £0.19, compared to a current price of £0.10 — trading 48.7% below its estimated fair value. The current Pretax Margin % is -54.24%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Abingdon Health (LSE:ABDX), the current Pretax Margin % is -54.24% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:ABDX has been successfully added to your 